ZGZeinab Gharaylou

Zeinab Gharaylou

*This is an algorithmically generated author record based on publicly available information.

Zeinab Gharaylou has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    DTI ‐ ALPS as a Biomarker of Small Vessel Disease Progression and Amyloid‐β in Normal Aging: A 3‐Year Longitudinal Study

    by Narges Azizi, Hoda Borooghani, Iman Kiani, Zeinab Gharaylou, Dina Seyedi, Kavous Firouznia, Shahriar Kolahi

    Cerebral small vessel disease (SVD) is a leading cause of stroke, vascular cognitive impairment, and functional decline in older adults. Emerging experimental and translational data implicate glymphatic dysfunction in SVD pathogenesis and in vascular amyloid accumulation. The analysis along the perivascular space (ALPS) index, derived from diffusion tensor imaging (DTI), noninvasively estimates water diffusivity along perivascular pathways and has been proposed as an indirect imaging marker related to glymphatic function. In this study, we aim to determine whether the baseline DTI‐ALPS index is associated with baseline SVD burden and subsequent longitudinal changes in SVD markers and amyloid‐β deposition in cognitively normal aging. We analyzed 204 cognitively normal participants from the Harvard Aging Brain Study with baseline and follow‐up visits separated by 3 years. Primary MRI SVD outcomes were intracranial‐volume–normalized white matter hyperintensities (WMH/ICV), and visual SVD ratings (Fazekas, ARWMC, perivascular space, and BOMBS [microbleed scale]). Secondary outcomes included cortical amyloid PET burden (PIB_FS_DVR_FLR). We tested the effects of time, baseline ALPS ( z ‐scored), and the time‐ALPS interaction using Bayesian mixed‐effects models with subject‐specific random intercepts adjusted for baseline age, sex, and education; amyloid models were additionally adjusted for APOE4 status. Continuous outcomes were modeled with Gaussian mixed‐effects models, binary outcomes with Bernoulli mixed‐effects models, and ordinal outcomes with Bayesian cumulative mixed‐effects models. In a sensitivity analysis, ALPS was recalculated after excluding voxels with λ 2 / λ 3 > 1.8, and the models were repeated using the crossing‐fiber‐adjusted index. Posterior means and 95% HDIs were the primary summaries. Multiplicity was controlled using the Benjamini–Hochberg false discovery rate procedure, and the resulting FDR‐adjusted two‐sided posterior tail‐area p ‐analogues are reported as p corrected . Over the 3‐year follow‐up, SVD and amyloid‐β burden increased: WMH/ICV ( β = 0.096, 95% HDI [0.069, 0.121], p corrected < 0.001), cortical amyloid‐β ( β = 0.130, 95% HDI [0.106, 0.152], p corrected < 0.001), Fazekas ( β = 0.320, 95% HDI [0.088, 0.541], p corrected = 0.010), ARWMC ( β = 0.404, 95% HDI [0.165, 0.649], p corrected = 0.004), basal ganglia ( β = 0.318, 95% HDI [0.079, 0.546], p corrected = 0.010), and centrum semiovale ( β = 0.244, 95% HDI [0.026, 0.450], p corrected = 0.025). PVS scores also increased over time. Higher baseline ALPS was associated with lower Fazekas severity ( β = −0.742, 95% HDI [−1.281, −0.201], p corrected = 0.026) and with attenuated amyloid accumulation over time ( β = −0.025, 95% HDI [−0.049, −0.001], p corrected = 0.039). In a sensitivity analysis excluding voxels with a high likelihood of substantial fiber crossing, the ALPS‐by‐time interaction for amyloid burden remained significant ( β = −0.028, 95% HDI [−0.052, −0.003], p corrected = 0.022), whereas the baseline association with Fazekas severity was attenuated ( β = −0.413, 95% HDI [−0.966, 0.181], p corrected = 0.751). Higher baseline WMH/ICV was associated with poorer baseline global cognition (PACC5) ( β = −0.092, 95% HDI [−0.177, −0.011], p corrected = 0.036), processing speed ( β = −0.116, 95% HDI [−0.223, −0.010], p corrected = 0.036), and executive function ( β = −0.144, 95% HDI [−0.251, −0.029], p corrected = 0.035). Higher baseline amyloid burden was associated with steeper PACC5 decline ( β = −0.065, 95% HDI [−0.096, −0.033], p corrected < 0.001). In cognitively normal older adults, higher conventional baseline ALPS was associated with lower Fazekas severity, although attenuation after crossing‐fiber adjustment indicates that this cross‐sectional relationship was sensitive to the microstructural composition of the ALPS regions. In contrast, higher baseline ALPS was associated with slower short‐term amyloid‐β accumulation, and this longitudinal association remained significant after crossing‐fiber adjustment. Greater baseline amyloid burden was associated with more rapid decline in global cognition, whereas higher baseline WMH volume was associated with poorer baseline global cognition, processing speed, and executive function. These findings support ALPS as a candidate noninvasive diffusion marker associated with longitudinal amyloid‐related change, while emphasizing the need for further validation of its relationship with SVD burden and its biological specificity.

  • Open Access

    Network-level and motor consequences of longitudinal perivascular diffusivity alterations indexed by DTI-ALPS in Parkinson’s disease

    by Zeinab Gharaylou, Narges Azizi, Fatemeh Shahbodaghy, Seyyed Mohammad Hosseini, Ahmadreza Sohrabi-Ashlaghi, Haady Ahmadzade, Sina Firouznia, Shahriar Kolahi

  • Open Access

    Structural and diffusion imaging in olfactory-related brain regions in Parkinson’s disease: predictors of clinical progression

    by Seyyed Mohammad Hosseini, Ahmadreza Sohrabi-Ashlaghi, Shahriar Kolahi, Narges Azizi, Hoda Borooghani, Zeinab Gharaylou, Samira Raminfard, Hossein Ghanaati, Hedayat Abbastabar, Amir Hossein Jalali, et al.

    Olfactory dysfunction is a prevalent non-motor symptom in Parkinson’s disease (PD). Structural and diffusion MRI studies suggest that olfactory-related brain regions undergo significant neurodegenerative changes in PD. The current study aims to explore the longitudinal structural and diffusion imaging in olfactory-related regions in PD over four years. The relationships between baseline imaging and fluid biomarkers, and subsequent cognitive and clinical changes were also explored. We analyzed 97 newly diagnosed early-stage PD patients from the Parkinson’s Progression Markers Initiative (PPMI) who underwent T1-weighted MRI, diffusion tensor imaging (DTI), and clinical assessments at baseline, two years, and four years. Structural and diffusion measures of olfactory-related regions were extracted using FreeSurfer and ExploreDTI. Baseline fluid biomarkers were also evaluated. Baseline mean diffusivity (MD) displayed significant associations with further cognitive changes across multiple regions, including amygdala, orbitofrontal cortex (OFC), insula, and thalamus (β=–0.214 to − 0.422). Baseline structural measures, including amygdala volume and entorhinal and OFC thickness, were associated with subsequent changes in cognitive and Unified Parkinson’s Disease Rating Scale (UPDRS) scores (β = 0.264 to 0.402). Moreover, baseline serum neurofilament-light chain levels predicted multiple cognitive score changes (β= − 0.603 to − 0.331). Longitudinal analyses revealed a significant MD increase in the thalamus along with gradual reductions in volume and cortical thickness in the amygdala, insula, OFC, and entorhinal cortex (FDR-adjusted p < 0.05). Linear mixed-effect models further confirmed thalamic diffusion metrics as a predictor of cognitive deterioration. Olfactory-related regions exhibit progressive neurodegeneration in early PD, contributing to worsening cognition and disease severity. Baseline imaging and fluid biomarkers may serve as prognostic tools in PD.


  • Reduced White Matter Fiber Density in Patients with Multiple Sclerosis

    by Zeinab Gharaylou, Fatemeh Shahbodaghy, Pirhossein Kolivand, Maryam Kolivand, Fatemeh Azizzadeh, Masoumeh Rostampour

    Introduction: Improved understanding of Multiple Sclerosis (MS) symptomatology, disease mechanisms, and clinical effectiveness can be achieved by investigating microstructural damage. The aim was to gain deeper insights into changes in white matter (WM) tracts in MS patients. Methods: Diffusion MRI-based tractography was utilized to segment WM tracts into regions of interest for further quantitative analysis. However, tractography is susceptible to false positive findings, reducing its specificity and clinical feasibility. To address these limitations, the Convex Optimization Modeling for Microstructure Informed Tractography (COMMIT) technique was employed. COMMIT was used to derive measures of intracellular (IC) and isotropic (ISO) compartments from multi-shell diffusion data of 40 healthy controls (HCs) and 40 MS patients. Results: The analysis revealed a widespread pattern of significantly decreased IC values in MS patients compared to HCs across 61,581 voxels (pFWE < 0.05, TFCE corrected). Similar WM structures studied using the fractional anisotropy (FA) value also showed a reduction in FA among MS patients compared to HCs across 57,304 voxels (pFWE < 0.05, TFCE corrected). Out of the 61,581 voxels exhibiting lower IC, a substantial overlap of 47,251 voxels (76.72%) also demonstrated lower FA in MS patients compared to HC. Discussion: The data suggested that lower IC values contributed to the explanation of FA reductions. Additionally, IC showed promising potential for evaluating microstructural abnormalities in WM in MS, potentially being more sensitive than the frequently used FA value.

  • Open Access

    Comorbidity in spinal cord injury in Iran: A narrative review

    by Taher Taheri, Saereh Hosseindoost, Hadi Kazemi, Seyedehalia Kamali, Pirhossein Kolivand, Zeinab Gharaylou

    Spinal cord injury (SCI) is a severe medical condition that affects millions of people worldwide each year. In Iran, an estimated 9 out of every 100,000 individuals experience traumatic SCI occurrences. Long-term disabilities and comorbidities stemming from SCI often necessitate multiple therapeutic interventions. The aim of this study is to evaluate the morbidity in Iranian SCI patients. In this study, a four-step process was used to select, extract, analyze, and synthesize relevant literature. The search covered 750 records from five databases, resulting in 25 articles included in the review. These articles, published between 2000 and 2023, utilized cross-sectional, qualitative, or cohort designs. The findings explored the prevalence, risk factors, and consequences of comorbidities associated with SCI, categorized into four themes: physical, sexual, psychological, and metabolic morbidity. Physical morbidity refers to medical conditions or complications affecting body functions or structures in SCI patients. The most frequently reported cases include pressure ulcers, pain, osteoporosis, fractures, impaired pulmonary function, renal failure, and obesity. Metabolic morbidity includes conditions such as vitamin D deficiency and cardiometabolic risk factors. Psychological morbidity encompasses depression, anxiety, and adjustment disorders. Sexual morbidity refers to conditions or complications affecting the sexual function or satisfaction of SCI patients. This narrative literature review offers a comprehensive examination of various aspects of SCI in Iranian patients. The review identifies numerous challenges and difficulties faced by SCI patients while also highlighting protective factors that can improve their well-being. Additionally, the review acknowledges gaps and limitations within the current literature and suggests possible avenues for future research.


  • Open Access

    Symmetry differences of structural connectivity in multiple sclerosis and healthy state

    by Fatemeh Shahbodaghy, Lida Shafaghi, Massoumeh Rostampour, Ali Rostampour, Pirhossein Kolivand, Zeinab Gharaylou


  • Open Access

    Psychosocial impact of COVID-19 2 years after outbreak on mental health of medical workers in Iran

    by Pirhossein Kolivand, Saereh Hosseindoost, Zahra Kolivand, Zeinab Gharaylou

    Background: The COVID-19 pandemic had a substantial influence on the mental health of healthcare workers. This study investigated general health status, the prevalence, and the severity of depressive spectrum and anxiety-related disorders. It evaluated the association between various factors and depression, anxiety, and stress among healthcare workers in the Khatam-Alanbia Hospital in Iran, after 2 years since the corona virus disease 2019 (COVID-19) pandemic. Results: In this online cross-sectional study, 409 participants were selected and given a questionnaire about demographic, personal, and clinical characteristics as well as stressors related to COVID-19. The participants completed the General Health Questionnaire (GHQ-28) and the 42-item Depression, Anxiety, and Stress Scale (DASS-42) to report depression, anxiety, and stress/tension levels. We found that the overall incidence of depression, anxiety and stress among health care workers during the COVID-19 pandemic was 44.25%, 50.62%, and 43.76%, respectively. Participants with severe to very severe depression, anxiety and stress accounted for 19.2%, 26.6%, and 18.2% of the sample, respectively. Being female was associated with higher odds of depression, anxiety, and stress. Conclusions: Two years after the COVID-19 outbreak, health workers are still showing a significant level of depression, anxiety, stress, and remarkable signs of psychological distress. The situation of a health care worker is worrying. The long-term psychological implications of infectious diseases should not be ignored. Mental health services could play an essential role in rehabilitation.


  • Open Access

    Analgesic Effect of Bumetanide on Neuropathic Pain in Patients With Spinal Cord Injury.

    by Farinaz Nasirinezhad, Leila Zarepour, Mahmoudreza Hadjighassem, Zeinab Gharaylou, Hossin Majedi, Fatemeh Ramezani

    The current study evaluated the analgesic effects of bumetanide as an adjunctive in the management of neuropathic pain following Spinal Cord Injury (SCI). The peripheral expression of Na-K-Cl Cotransporter-1 (NKCC1) and K-Cl Cotransporter-2 (KCC2) genes in polymorphonuclear lymphocytes (PMLs) was assessed as a possible biomarker indicating central mechanisms underlying the observed response. Through an open-label, single-arm, pilot trial of bumetanide (2 mg/d), an add-on treatment was conducted on 14 SCI patients for 19 weeks. This study consisted of 3 phases: pre-treatment (1 month), titration (3 weeks), and active treatment (4 months). Ultimately, 9 patients completed the study. The primary outcome variables were the endpoint pain score using the Numeric Rating Scale (NRS), and also the short-form of the McGill pain questionnaire. Secondary endpoints included the short-form of the health survey that assesses the quality of life. Blood samples were collected and used for determining the expression of NKCC1 and KCC2 genes in transcription and translation levels. Bumetanide treatment significantly decreased average pain intensity according to the NRS and the short-form of the McGill pain questionnaire scores. Baseline expression of KCC2 protein was low between groups and increased significantly following treatment (P<0.05). In the current study, pain improvement was accompanied by the greater mean change from the baseline (improvement) for the overall quality of life. These data highlighted the analgesic effect of bumetanide on neuropathic pain and indicated the potential role of the upregulation of KCC2 protein and involvement of GABAergic disinhibition in producing neuropathic pain.